Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia.

Pukhraj Rishi,Daraius Shroff,Ekta Rishi

Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia.

2008

Pukhraj Rishi
Daraius Shroff
Ekta Rishi

Background To report the efficacy of combination photodynamic therapy and intravitreal ranibizumab for juxtafoveal, subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia (IMT).

Keywords:

Ranibizumab
Ophthalmology
Anatomy
Macular telangiectasia
Subretinal neovascular membrane
Visual acuity
Combination therapy
Photodynamic therapy
Medicine
Adverse effect
primary treatment
intravitreal ranibizumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations